As perennial powerhouses Merck and Pharmacia prepare for fierce competition between their respective second- generation COX-2 Inhibitor products, Pharmacia lands the first blow with Bextra (valdecoxib) reaching market first. Pharmacia's two new second- generation COX-2 Inhibitors are valdecoxib and parecoxib (Dynastat). The former is an oral formulation for the treatment of dysmenorrhea, Rheumatoid Arthritis (RA), and Osteoarthritis (OA), and the latter is an injectable formulation for perioperative care (encompassing pain before, during, and after surgery). Having both products approved will give Pharmacia a marketing advantage because patients who are given injectable therapy in the hospital may be switched to the oral version upon discharge.

(Photo: )

In late 2001, Pharmacia received FDA approval for valdecoxib, which the company will begin promoting with Pfizer in April 2002. Valdecoxib's potential advantage over its predecessor, celecoxib (Celebrex), is a longer duration of action that would make once-daily dosing possible. Valdecoxib is heralded as a once-a-day, 10 mg dose that offers 24-hour arthritis relief. Celecoxib often requires twice-daily dosing for sustained therapeutic effect.

Market Outlook for COX-2 Inhibitors, a new report from Decision Resources, Inc., evaluates the market for COX-2 inhibitors in five indications:

  * Osteoarthritis.   * Rheumatoid arthritis.   * Moderate to severe chronic low back pain.   * Colorectal cancer.   * Mild cognitive impairment.  

Based on a 2000-2010 study and forecast period, Market Outlook for COX-2 Inhibitors provides the following:

  * Epidemiology of the five indications under study.   * Estimates of target populations for drug therapy.   * Prescribing patterns for these agents.   * In-depth analysis of unmet clinical needs.   * Analysis of emerging agents.   * Evaluation of opportunity for COX-2 inhibitors in the five indications.  

To order your copy of Market Outlook for COX-2 Inhibitors call Frank Sama at 781-296-2553 or email

Market Outlook for COX-2 Inhibitors is part of the Immune and Inflammatory Disorders portfolio, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at

Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or

In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or

In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or



AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,

Decision Resources Presents a Live Teleconference on Corporate Investment and Business Trends in Drug Discovery

View Now